Trial Profile
A Phase I/II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (Vidaza) in Intermediate-2 and High Risk MDS Patients.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Dec 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 24 May 2019 Status changed from active, no longer recruiting to completed.
- 28 Oct 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 28 Oct 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.